Aleor Dermaceuticals receives USFDA approval for Nystatin and Triamcinolone Acetonide Ointment

13 Mar 2022 , 01:33 AM

Alembic Pharmaceuticals Alembic today announced that its joint venture Aleor Dermaceuticals Aleor has received final approval from the US Food Drug Administration USFDA for its Abbreviated New Drug Application ANDA for Nystatin and Triamcinolone Acetonide Ointment USP 100000 unitsgram The approved ANDA is therapeutically equivalent to the reference listed drug product RLD Nystatin and Triamcinolone Acetonide Ointment USP 100000 Ug01 Percentage of Taro Pharmaceuticals USA Inc Nystatin and Triamcinolone Acetonide Ointment is indicated for the treatment of cutaneous candidiasis; it has been demonstrated that the nystatin-steroid combination provides greater benefit than the nystatin component alone during the first few days of treatment